Company Profile

Lumiphore Inc
Profile last edited on: 8/11/16      CAGE: 4LCX5      UEI: K95KLV3N3XD9

Business Identifier: Proprietary lanthanide technology for use in high-value applications
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4677 Meade Street Suite 216
Richmond, CA 94804
   (510) 232-8455
Location: Single
Congr. District: 11
County: Contra Costa

Public Profile

Lumiphore Inc is an early stage research company developing proprietary lanthanide technology for use in high-value applications. The market for fluorescent reagents in biology is more than $1.0 billion and is growing 25% annually. Demand is greatest for reagents with sensitivity better than can be achieved with organic fluorescent molecules. It is generally recognized that lanthanide reporters show great promise for increased sensitivity, however, the development of good lanthanides has lagged. The firm’s highly fluorescent and flexible lanthanide compounds are a new kind of ultrasensitive fluorophore that overcome the sensitivity limitation. Lumiphore develops and markets biological detection reagents based on proprietary fluorescent lanthanide complexes, which provide an unparalleled combination of sensitivity, reliability, flexibility and high throughput. Uniquely among fluorescent reagents, lanthanides make possible time-resolved detection: fluorescence of Lumiphore’s Terbium complex outlasts fluorescence of other molecules so that gated detection results in vastly improved signal-to-noise. Fluorescence of complexes made with Europium, Dysprosium and Samarium last as long as Terbium but emit at entirely different colors, permitting for the first time simultaneous multi-channel fluorescent testing. Lumiphore plans to use this technology in a variety of applications: clinical uses, pharmaceutical and biotechnological research and development, and imaging. To maximize initial sales and profits, the firm intends to leverage its unparalleled technology to generate profits that will enable it to advance its technology and support entry into other marke

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  Scott King

  Kenneth Raymond -- President; Chairman

  Stephen H Blose -- Chief Business Development Officer

  Nathanel G Butlin -- Chief Scientific Consultant

  Todd M Corneillie -- Vice President of Research

  Darren J Magda -- Vice President, Research & Development

  Willem Spiegel -- Treasurer and Acting CFO

Company News

There are no news available.